Study of XL999 in Patients With Previously Treated Ovarian Cancer

Inclusion Criteria:

Female patients with a histologically confirmed diagnosis of metastatic ovarian cancer
Measurable disease according to Response Criteria for Solid Tumors (RECIST)
Prior treatment with platinum-based therapy
Platinum-sensitive or platinum-resistant disease
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Life expectancy of ≥3 months
Adequate organ and marrow function
Signed informed consent
No other malignancies within 5 years

Exclusion Criteria:

Radiation to ≥25% of bone marrow within 30 days of XL999 treatment
Use of an investigational drug or cytotoxic chemotherapy within 30 days of XL999 treatment
Prior anticancer therapy targeting VEGF (eg, bevacizumab, sorafenib, or sunitinib)
More than two prior systemic non-platinum cytotoxic chemotherapy regimens
Subject has not recovered to grade ≤1 or to within 10% of baseline from adverse events due to other medications administered >30 days prior to study enrollment
History of or known brain metastases, current spinal cord compression, or carcinomatous meningitis
Uncontrolled and/or intercurrent illness
Patients who are pregnant or breastfeeding
Known human immunodeficiency virus (HIV)